Congress mandates faster drug access for autoimmune patients, limits insurer gatekeeping

What it does

This bill requires health insurance plans to cover drugs used to treat autoimmune diseases and blood disorders (like hemophilia and Von Willebrand disease) without prior authorization restrictions. Specifically, insurers cannot require prior authorization more than once per year for these drugs, except for drugs used short-term, controlled substances, or those with FDA-mandated safety monitoring. The requirement applies to group health plans and individual insurance markets starting January 1, 2027.

Why we flagged it

The bill's core mechanism is a mandate to reduce prior authorization barriers for a specific drug class, framed as a patient-access measure. It is not a price-control or coverage-expansion bill in the traditional sense—it removes administrative friction rather than expanding the drug formulary or capping costs.

What the text implies

• Insurers may respond by narrowing formularies or raising premiums for plans covering autoimmune/blood disorder drugs, shifting cost burden to patients through higher out-of-pocket maximums or plan-selection friction.
• The one-per-year prior authorization limit may incentivize insurers to deny the initial authorization more aggressively, knowing they cannot re-review mid-year, concentrating gatekeeping at the first decision point.
• Drugs with FDA Risk Evaluation and Mitigation Strategies (REMS) remain exempt from the one-per-year cap, potentially creating a two-tier system where REMS-required drugs face repeated authorization while non-REMS drugs do not.
• The bill does not address cost-sharing (copays, coinsurance, deductibles), so patients may still face high out-of-pocket costs even with guaranteed coverage and reduced prior authorization.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with autoimmune and blood disorders gain faster access to necessary medications by reducing prior authorization delays and repetitive approval processes. The restriction on insurers' ability to repeatedly deny or delay coverage removes a significant barrier to treatment, though the bill preserves safety guardrails for high-risk drug classes.

Who stands to gain

• Pharmaceutical manufacturers of autoimmune and blood disorder drugs
• Specialty pharmacy networks and PBM intermediaries (if they capture administrative savings)
• Patients with autoimmune diseases and blood disorders (non-financial: health/access benefit)

Named in the bill

Employee Retirement Income Security Act (ERISA), Public Health Service Act, Internal Revenue Code, FDA (Food and Drug Administration), Risk Evaluation and Mitigation Strategy (REMS), Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY), AIG, Fiserv (FBK), Prudential (PRU)

Where it stands

2 cosponsors: 2 Republicans.

• Jun 8, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 8, 2026 — Referred to House Committee on Ways and Means and House Committee on Education and Workforce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 5 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $5,720,100 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

• American Medical Association — $5,643,000 on 2 filings
• American Society for Gastrointestinal Endoscopy — $30,000 on 1 filing
• North American Society for Pediatric Gastroenterology, Hepatology and Nutrition — $25,500 on 1 filing
• American College of Osteopathic Internists — $21,600 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.